Oxford Covid-19 vaccine is still possible this year, says AstraZeneca chief

Pharmaceutical firm’s boss says 2020 deadline possible if regulators move fast

AstraZeneca’s coronavirus vaccine could still be available by the end of the year, or early next year, according to the company’s chief executive, Pascal Soriot, despite clinical trials being paused after a volunteer fell ill.

AstraZeneca and Oxford University, which are jointly developing the vaccine and testing it on 50,000 to 60,000 people around the world, halted trials on Wednesday to investigate the “potentially unexpected illness” of one participant.

Soriot was unable to say when the trial would resume, but said “I still think we are on track for having a set of data that we would submit before the end of the year” for regulatory approval.

They “could still have a vaccine by the end of this year, early next year”, depending on how fast the regulator moves, he added.

Speaking at an event hosted by the media group Tortoise, the AstraZeneca boss said it was not unusual to pause trials because of “adverse events”.

“It’s very common, actually, and many experts will tell you this,” he said. “The difference with other vaccine trials is the whole world is not watching them. They stop, they study and they restart.”

Sign up to the daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

The woman who has fallen ill will undergo further testing. The data will then be submitted to an independent safety committee, which will assess it to decide whether trials can resume.

She reportedly had neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis.

Soriot said: “We don’t know if it’s transverse myelitis … We don’t know what the final diagnosis is.”

Transverse myelitis can be treated by steroids to reduce the inflammation but the condition can be permanent.

AstraZeneca has struck a number of manufacturing partnerships around the world and believes it will be able to manufacture about 3bn doses.

Soriot said he was confident that combined with the vaccines being developed by other pharmaceutical firms, there would be enough vaccines for the entire world population.

He said the vaccine would be supplied to countries at the same time to ensure fair and equitable distribution.


Julia Kollewe

The GuardianTramp

Related Content

Article image
Oxford AstraZeneca vaccine to be sold to developing countries at cost price
Jab that is part of global initiative to distribute doses will remain at low price ‘in perpetuity’

Peter Beaumont

23, Nov, 2020 @4:14 PM

Article image
What difference will Oxford/AstraZeneca vaccine make in UK?
We look at how the introduction of a new vaccine in the fight against Covid will work

Sarah Boseley

01, Jan, 2021 @5:57 PM

Article image
Covid: hopes for Oxford nasal vaccine dealt blow after poor trial results
Scientists ditch plans to develop nasal spray version of Oxford/AstraZeneca vaccine in its current form

Ian Sample Science editor

10, Oct, 2022 @11:01 PM

Article image
Vaccine results bring us a step closer to ending Covid, says Oxford scientist
Latest breakthrough comes as PM says he hopes most at-risk could be immunised by Easter

Sarah Boseley Health editor

23, Nov, 2020 @8:33 PM

Article image
'It's a great day': Oxford coronavirus vaccine volunteers on trial data
Trial participants react to news that Oxford AstraZeneca Covid vaccine has up to 90% efficacy

Ben Quinn

23, Nov, 2020 @2:05 PM

Article image
AstraZeneca partners with Oxford University to produce Covid-19 vaccine
Drugmaker will manufacture and distribute vaccine if human trials are successful

Joanna Partridge

30, Apr, 2020 @4:50 PM

Article image
AstraZeneca sales of Covid vaccine triple to $1.2bn in first half of 2021
Not-for-profit pledge sees British firm’s sales revenue fall significantly short of US rival Pfizer

Julia Kollewe

29, Jul, 2021 @2:58 PM

Article image
Oxford Covid vaccine trial suspension: what happens next?
Tests have been paused after a UK volunteer became ill. How will it affect the search for a cure?

Sarah Boseley Health editor

09, Sep, 2020 @11:23 AM

Article image
Oxford University Covid-19 vaccine firm says it is not in talks with Trump
AstraZeneca insists it has not discussed ‘emergency use authorisation’ with the US

Peter Beaumont and Sarah Boseley

24, Aug, 2020 @12:28 PM

Article image
Oxford offers best hope for Covid-19 vaccine this year, MPs told
University is leading rivals but first drugs may not work fully, says vaccine taskforce chair

Sarah Boseley Health editor

01, Jul, 2020 @6:43 PM